Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Name: Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Published: 2026
License: Public Domain

Fujian Cancer Hospital · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

breast-neoplasms

breast diseases, breast neoplasms, dalpiciclib, endocrine breast diseases, cdk4/6 inhibitor, hr+/her2- breast cancer, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Related documents